Jones A L, O'Brien M E, Lorentzos A, Viner C, Hanrahan A, Moore J, Millar J L, Gore M E
Department of Medicine, Royal Marsden Hospital, London, U.K.
Cancer Chemother Pharmacol. 1992;30(1):73-6. doi: 10.1007/BF00686489.
Laboratory data suggest a synergistic interaction between carmustine (BCNU) and tumour necrosis factor (TNF) in melanoma. We therefore studied the activity of 200 mg/m2 BCNU given alone or in combination with 88 micrograms/m2 recombinant human TNF-alpha (rhTNF alpha) as a daily i.v. infusion for 5 days at 48-day intervals to patients with metastatic melanoma. In this randomised phase II trial, the rate of response to BCNU alone was 20% [95% confidence interval (CI), 2%-38%], and this was not improved by the addition of TNF (response rate, 10.5%; 95% CI, 1.3%-33%). Toxicity was higher in the combination arm, and there was no difference in survival.
实验室数据表明，卡莫司汀（BCNU）与肿瘤坏死因子（TNF）在黑色素瘤中存在协同相互作用。因此，我们对转移性黑色素瘤患者进行了研究，以200mg/m²的BCNU单独给药，或与88μg/m²重组人TNF-α（rhTNFα）联合给药，每天静脉输注，持续5天，间隔48天。在这项随机II期试验中，单独使用BCNU的缓解率为20%[95%置信区间（CI），2%-38%]，添加TNF后缓解率并未提高（缓解率为10.5%；95%CI，1.3%-33%）。联合治疗组的毒性更高，生存率无差异。
